Emma Boyle Email

Financial Consultant . Neumentum

Morristown, NJ

Location

Current Roles

Employees:
7
Revenue:
$1.1M
About
Neumentum is dedicated to becoming a leading non-opioid analgesic and neurology specialty pharmaceutical company with product candidates that have the potential to provide the benefits of safe and effective pain management without the risks of abuse, misuse and diversion seen with opioids, or opioid-induced side effects including potentially life-threatening respiratory depression. Neumentum has two lead product candidates being developed to directly help address the opioid crisis. NTM-006, a Phase 2 novel oral analgesic with a target indication for moderate to moderately severe chronic pain, was licensed in late 2019 from Janssen Pharmaceuticals NV and McNeil Consumer Pharmaceuticals Co., both part of the Johnson & Johnson Family of Companies. NTM-001 is a Phase 3-ready IV formulation of Toradol (ketorolac), with recent Phase I results showing that it may provide consistent, steady blood plasma levels of ketorolac over 24 hours and durable analgesic effect. This Phase I study is part of a program supporting what has the potential to be the first-ever NSAID approved for continuous infusion. Neumentum is led by a world-wide executive team of biotech and pharmaceutical industry leaders who have extensive experience in pain and neurology, from drug development through commercialization. For more information, visit www.Neumentum.com.
Neumentum Address
252 Colorado Avenue
Morristown, NJ
United States
Neumentum Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.